Characterization of Non-Responders to IL-17 inhibitors in Moderate to Severe Psoriasis Patients Enrolled in the Corrona® Psoriasis Registry.

While interleukin-17 (IL-17) inhibitors are effective for many patients with psoriasis, there is limited real-world data characterizing patients who respond or do not respond to this biologic class.1 Identification of patient characteristics associated with response to this class of medication would present a significant advantage for both patients and physicians. For this reason, we have conducted a retrospective characterization of non-response to IL-17 inhibitors in patients with moderate-severe psoriasis.